decreased insulin sensitivity Insulin resistance
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: - Participants are able to provide signed and dated written informed consent prior to any study specific procedures - Participants should have suitable veins for cannulation or repeated venipuncture - Women are post-menopausal (defined as at least 1 year post cessation of menses) - Aged >= 45 and 5kg in the past 3 months) - Sedentary lifestyle (not more than 2 hours of sports per week) - No signs of active cardiovascular disease, liver or kidney malfunction - Liver fat content >= 2% weight/weight.
Exclusion criteria
Exclusion criteria: - Type 2 diabetes - Previous enrolment in a clinical study with an investigational product during the last 3 months or as judged by the Investigator - Patients with congestive heart failure and and/or severe renal and or liver insufficiency or another condition that may interfere with outcomes measured in this study - Any contra-indication MRI scanning - Alcohol consumption of >2 servings per day for men and >1 servings per day for woman - Smoking in the past 6 months - Men: Hb
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome is hepatic insulin sensitivity (suppression of EGP during clamp) upon a 4-week high SFA diet versus a 4-week fructose diet. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcomes are: - de novo lipogenesis upon 4-week high SFA versus 4-week high fructose diet - change in (baseline-end intervention) hepatic SFA fraction upon 4-week high SFA versus 4-week high fructose. | — |
Countries
Netherlands